Koers Kuros Biosciences AG Swiss Exchange
Aandelen
CH0325814116
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 17,99 mln. 19,67 mln. 18,39 mln. | Omzet 2023 | 33,56 mln. 36,7 mln. 34,32 mln. | Marktkapitalisatie | 128 mln. 140 mln. 131 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -14 mln. -15,31 mln. -14,32 mln. | Nettowinst (verlies) 2023 | -13 mln. -14,21 mln. -13,29 mln. | EV/omzet 2022 | 1,76 x |
Nettoliquiditeiten 2022 | 22,08 mln. 24,15 mln. 22,58 mln. | Nettoliquiditeiten 2023 | 12 mln. 13,12 mln. 12,27 mln. | EV/omzet 2023 | 3,46 x |
K/w-verhouding 2022 |
-3,41
x | K/w-verhouding 2023 |
-9,18
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 64,71% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 17-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 14-06-18 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 19-04-21 |
Joost de Bruijn
FOU | Founder | 58 | 04-12-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |